Genezen’s New Viral Vector Process Development Lab

Scroll Down

Our new state-of-the-art, cGMP-compliant multi-vector process development facility is now open!

December 7, 2021 – Our deep expertise in development and manufacture of viral vectors coupled with this new facility and equipment will accelerate our partners’ abilities to advance life-saving therapies into the clinic.

The lab will deliver a full suite of process development capabilities to support cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation from the site. Learn more about the facility’s capabilities here.

You may also be interested in...

Genezen Enters Licensing Agreement with CSL…

February 21, 2024 – Genezen, a leading cell and gene therapy...

Read more

Bringing Therapies to Life with Multi-Vector…

Rapid expansion in biotechnology platforms and advancement in genetic editing technologies...

Read more

LVV Approaches to Pseudotyping and Plasmid…

As cell and gene therapies continue to provide unprecedented advancements in...

Read more

Genezen Announces the Appointment of Steven…

BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...

Read more